top of page
  • Patient Education

Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy

Updated: Mar 27, 2022

Patient Education: Idecabtagene Vicleucel

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

IDE-CEL (Abecma) CART Cell Therapy for Multiple Myeloma

Idecabtagene Vicleucel ( Abecma)

NIH National cancer institute - site info

This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s): Abecma

FDA Approved: Yes

Learn more:


MedlinePlus Information

A lay language summary of important information about this drug that may include the following:

warnings about this drug,

what this drug is used for and how it is used,

what you should tell your doctor before using this drug,

what you should know about this drug before using it,

other drugs that may interact with this drug, and

possible side effects.

Learn more:


Information on Abecma website



Understanding ABECMA® (idecabtagene vicleucel)

Understanding ABECMA® (idecabtagene vicleucel) | International Myeloma Foundation

Download Booklet here

IMF Understanding Series

IMF Resource Library

Current FDA-Approved Medications for Multiple Myeloma Treatment



All about Abecma (Idecabtagene Vicleucel)

Watch Video on YouTube

HealthTree University for Multiple Myeloma Lectures

Health Tree University Myeloma Videos



Standard Treatments - (BCMA)-directed personalized immunotherapy Abecma

MMRF Education Programs

MMRF Videos


References ABECMA- idecabtagene vicleucel:

FDA Label Prescribing Information (Revised 03/2021)

Prescribing Information | ABECMA

Medication Guide

Drug Label Information at DAILYMED - NIH-National Library of Medicine

DailyMed - ABECMA- idecabtagene vicleucel suspension

Other Resources

Resources & Support


- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

Posts Archive
bottom of page